Meyka Pro banner
Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research Company Limited Fundamental Analysis (NSE: SPARC.NS)

SPARC.NS●NSE
HealthcareDrug Manufacturers - Specialty & Generic
₹190.16
₹2.41(1.25%)
Indian Market opens in 38h 20m

Sun Pharma Advanced Research Company Limited Fundamental Analysis (NSE: SPARC.NS)

Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS) shows moderate financial fundamentals with a PE ratio of 3.77, profit margin of 84.68%, and ROE of 1.73%. The company generates $19.3B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

Operating Margin84.26%
Cash Position21.00%
PEG Ratio0.01
Current Ratio7.65

Areas of Concern

ROE1.73%
We analyze SPARC.NS's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of 81.2/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.

Fundamental Health Score

B+
81.2/100

We analyze SPARC.NS's fundamental strength across five key dimensions:

Efficiency Score

Excellent

SPARC.NS demonstrates superior asset utilization.

ROA > 10%
97.74%

Valuation Score

Excellent

SPARC.NS trades at attractive valuation levels.

PE < 25
3.77
PEG Ratio < 2
0.01

Growth Score

Moderate

SPARC.NS shows steady but slowing expansion.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

SPARC.NS maintains a strong and stable balance sheet.

Debt/Equity < 1
0.00
Current Ratio > 1
7.65

Profitability Score

Moderate

SPARC.NS maintains healthy but balanced margins.

ROE > 15%
173.32%
Net Margin ≥ 15%
84.68%
Positive Free Cash Flow
No

Key Financial Metrics

Is SPARC.NS Expensive or Cheap?

P/E Ratio

SPARC.NS trades at 3.77 times earnings. This suggests potential undervaluation.

3.77

PEG Ratio

When adjusting for growth, SPARC.NS's PEG of 0.01 indicates potential undervaluation.

0.01

Price to Book

The market values Sun Pharma Advanced Research Company Limited at 4.29 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

4.29

EV/EBITDA

Enterprise value stands at 4.38 times EBITDA. This is generally considered low.

4.38

How Well Does SPARC.NS Make Money?

Net Profit Margin

For every $100 in sales, Sun Pharma Advanced Research Company Limited keeps $84.68 as profit after all expenses.

84.68%

Operating Margin

Core operations generate 84.26 in profit for every $100 in revenue, before interest and taxes.

84.26%

ROE

Management delivers $1.73 in profit for every $100 of shareholder equity.

1.73%

ROA

Sun Pharma Advanced Research Company Limited generates $97.74 in profit for every $100 in assets, demonstrating efficient asset deployment.

97.74%

Following the Money - Real Cash Generation

Operating Cash Flow

Sun Pharma Advanced Research Company Limited generates limited operating cash flow of $0.00, signaling weaker underlying cash strength.

$0.00

Free Cash Flow

Sun Pharma Advanced Research Company Limited generates weak or negative free cash flow of $0.00, restricting financial flexibility.

$0.00

FCF Per Share

Each share generates $0.00 in free cash annually.

$0.00

FCF Yield

SPARC.NS converts 0.00% of its market value into free cash.

0.00%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

3.77

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.005

vs 25 benchmark

P/B Ratio

Price to book value ratio

4.29

vs 25 benchmark

P/S Ratio

Price to sales ratio

3.19

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.002

vs 25 benchmark

Current Ratio

Current assets to current liabilities

7.65

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.73

vs 25 benchmark

ROA

Return on assets percentage

0.98

vs 25 benchmark

ROCE

Return on capital employed

1.09

vs 25 benchmark

How SPARC.NS Stacks Against Its Sector Peers

MetricSPARC.NS ValueSector AveragePerformance
P/E Ratio3.7730.24 Better (Cheaper)
ROE173.32%540.00% Weak
Net Margin84.68%-2322.00% (disorted) Strong
Debt/Equity0.000.08 Strong (Low Leverage)
Current Ratio7.655.59 Strong Liquidity
ROA97.74%-17516.00% (disorted) Strong

SPARC.NS outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Sun Pharma Advanced Research Company Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ